Cigna Group (NYSE:CI) Stock Rating Reaffirmed as “Outperform” by Royal Bank Of Canada

Cigna Group (NYSE:CI)‘s stock had its “outperform” rating reiterated by analysts at Royal Bank Of Canada in a report released on Thursday, Benzinga reports. They currently have a $337.00 target price on the health services provider’s stock. Royal Bank Of Canada’s price target indicates a potential upside of 25.78% from the company’s previous close.

Other analysts have also recently issued reports about the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Cigna Group in a report on Thursday, August 27th. Robert W. Baird set a $362.00 price target on shares of Cigna Group in a report on Friday, July 31st. Mizuho upped their price target on shares of Cigna Group from $330.00 to $340.00 and gave the company an “outperform” rating in a report on Monday, June 8th. Barclays upped their price target on shares of Cigna Group from $304.00 to $310.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Finally, Wall Street Zen raised shares of Cigna Group from a “hold” rating to a “buy” rating in a report on Saturday, September 26th. Fifteen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $337.10.

Cigna Group Stock Down 1.4%

Shares of NYSE CI traded down $3.90 during trading on Thursday, reaching $267.93. 856,613 shares of the stock were exchanged, compared to its average volume of 1,678,667. The company has a market capitalization of $70.80 billion, a price-to-earnings ratio of 11.05, a price-to-earnings-growth ratio of 0.93 and a beta of 0.31. The business’s 50-day moving average price is $279.53 and its 200 day moving average price is $280.55. The company has a quick ratio of 0.76, a current ratio of 0.76 and a debt-to-equity ratio of 0.68. Cigna Group has a twelve month low of $239.51 and a twelve month high of $315.47.

Cigna Group (NYSE:CI) last posted its quarterly earnings results on Thursday, July 30th. The health services provider reported $7.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.60 by $0.18. The firm had revenue of $71.56 billion for the quarter, compared to analysts’ expectations of $70.14 billion. Cigna Group had a net margin of 2.27% and a return on equity of 19.75%. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the company posted $7.20 earnings per share. Cigna Group has set its FY 2026 guidance at 30.450- EPS. As a group, equities analysts forecast that Cigna Group will post 30.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other Cigna Group news, insider Nicole S. Jones sold 2,677 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $279.61, for a total transaction of $748,515.97. Following the sale, the insider directly owned 25,880 shares of the company’s stock, valued at approximately $7,236,306.80. This represents a 9.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Everett Neville sold 617 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $284.05, for a total transaction of $175,258.85. Following the sale, the insider directly owned 5,053 shares in the company, valued at $1,435,304.65. This trade represents a 10.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 22,730 shares of company stock worth $6,293,359 over the last three months. 0.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Cigna Group

Several institutional investors have recently modified their holdings of CI. GQG Partners LLC bought a new position in shares of Cigna Group during the second quarter worth about $1,628,918,000. Bank of America Corp DE bought a new position in shares of Cigna Group during the second quarter worth about $827,692,000. Legal & General Group Plc bought a new position in shares of Cigna Group during the second quarter worth about $542,779,000. Boston Partners grew its position in shares of Cigna Group by 314.6% during the fourth quarter. Boston Partners now owns 1,638,191 shares of the health services provider’s stock worth $450,856,000 after acquiring an additional 1,243,056 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Cigna Group during the second quarter worth about $241,312,000. Institutional investors own 86.99% of the company’s stock.

Key Stories Impacting Cigna Group

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Cigna introduced its “Lead to One” strategy, focusing on complex care, specialty pharmacy, affordability, personalization, data, technology and artificial intelligence. Management targets 10%–14% adjusted EPS compound annual growth through 2030, offering a potentially significant long-term earnings-growth catalyst. Cigna Investor Day announcement
• Positive Sentiment: The company plans to invest $3 billion in a multiyear modernization and productivity initiative. Although costly initially, Cigna expects the program to improve workflow, performance and operating efficiency. Increased investment in specialty pharmacy and complex care could also strengthen Evernorth’s competitive position. Cigna specialty pharmacy investment article
• Positive Sentiment: Royal Bank of Canada reaffirmed an “outperform” rating and set a $337 price target, implying roughly 26% upside from the cited share price. A separate Seeking Alpha analysis characterized CI as undervalued and forecast double-digit EPS growth. Cigna valuation analysis
• Neutral Sentiment: Cigna reaffirmed its 2026 EPS guidance of approximately $30.45 and revenue guidance of $280 billion. The company also announced an exclusive agreement involving Cigna’s international health benefits business and UnitedHealthcare Global, potentially supporting its international platform, although the financial impact was not specified. Cigna international agreement
• Negative Sentiment: The 2026 revenue outlook of $280 billion is below the roughly $287.2 billion analyst consensus, while EPS guidance of $30.45 is slightly below the $30.51 consensus estimate. The $3 billion investment program may also create near-term expense and execution concerns, helping explain why the stock has decreased despite the favorable long-term targets. Cigna financial targets

Cigna Group Company Profile

The Cigna Group (NYSE: CI) is a global health company that provides health care and related services to individuals, employers, government organizations and health plans. Its operations are primarily organized through Cigna Healthcare and Evernorth Health Services, which together address health coverage, pharmacy services, care delivery and benefit management.

Cigna Healthcare offers medical, dental, behavioral health, disability and other benefits, with a focus on employer-sponsored and individual health plans in the United States as well as international health services.